Socrates Health Solutions, Developer of Socrates Companion™ Noninvasive Blood Glucose Self-Monitoring Device, Announces Expanded Role of John Maynard

Published: Apr 12, 2018

DALLAS--(BUSINESS WIRE)-- Socrates Health Solutions announces the appointment of John Maynard to the role of special advisor, bringing to Socrates more than 25 years of experience developing and commercializing non-invasive medical diagnostic devices.

Maynard was a co-founder and executive vice president of VeraLight which commercialized SCOUT DS, a non-invasive diabetes screening device. Prior to VeraLight, he was a co-founder and vice president of engineering at InLight Solutions, which had a 10-year strategic partnership with the LifeScan division of Johnson & Johnson to develop a noninvasive glucose measurement device. Maynard holds a master’s degree in electrical engineering from Stanford University and has published over 20 peer-reviewed journal articles related to diabetes and its complications.

Learn more about John and recent developments at Socrates at: www.socrateshealthsolutions.com.

“Socrates has worked closely with John developing our patient testing protocols and broader regulatory planning,” says Scott Smith, CEO, Socrates. “With our recent technology advances, we see John playing a pivotal role in our engineering, quality and manufacturing practices.”

Douglas Sutherland, Chairman of the Board of Directors, explains, “With John’s expertise and experience, we have found an individual uniquely qualified to support the conversion of Socrates’ scientific advancements into products ready for broader patient testing, manufacturing and regulatory approval processes.”

About Socrates Health Solutions, Inc.

Socrates Health Solutions, Inc. is a medical device company focused on the design, development and commercialization of self-monitoring blood glucose (SMBG) and continuous glucose monitoring (CGM) solutions which are non-invasive and inexpensive. These devices have not yet been cleared by the FDA and are currently not for sale.

Back to news